DDInter1123 DDInter1331
Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. Mannitol may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a renal function diagnostic aid. On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for this indication under the name BRONCHITOL® by Chies
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production. Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period. Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
Mannitol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Mannitol {u} (Compound) palliates {v} (Disease) glaucoma
glaucoma {u} (Disease) is treated by {v} (Compound) Timolol
Timolol {u} may lead to a major life threatening interaction when taken with {v} Olodaterol
Mannitol {u} (Compound) is included by {v} (Pharmacologic Class) Increased Diuresis
Increased Diuresis {u} (Pharmacologic Class) includes {v} (Compound) Bendroflumethiazide
Bendroflumethiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Mannitol {u} (Compound) palliates {v} (Disease) glaucoma
glaucoma {u} (Disease) is treated by {v} (Compound) Methazolamide
Methazolamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Mannitol {u} (Compound) causes {v} (Side Effect) Discomfort
Discomfort {u} (Side Effect) is caused by {v} (Compound) Bisoprolol
Bisoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Mannitol {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Olodaterol
Mannitol {u} (Compound) palliates {v} (Disease) glaucoma
glaucoma {u} (Disease) is palliated by {v} (Compound) Epinephrine
Epinephrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Mannitol {u} (Compound) causes {v} (Side Effect) Oropharyngeal pain
Oropharyngeal pain {u} (Side Effect) is caused by {v} (Compound) Nadolol
Nadolol {u} may lead to a major life threatening interaction when taken with {v} Olodaterol
Mannitol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Carvedilol
Carvedilol {u} may lead to a major life threatening interaction when taken with {v} Olodaterol
Mannitol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Mannitol (Compound) palliates glaucoma (Disease) and glaucoma (Disease) is treated by Timolol (Compound) and Timolol may lead to a major life threatening interaction when taken with Olodaterol
Mannitol (Compound) is included by Increased Diuresis (Pharmacologic Class) and Increased Diuresis (Pharmacologic Class) includes Bendroflumethiazide (Compound) and Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Mannitol (Compound) palliates glaucoma (Disease) and glaucoma (Disease) is treated by Methazolamide (Compound) and Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Mannitol (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Bisoprolol (Compound) and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Mannitol (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Mannitol (Compound) palliates glaucoma (Disease) and glaucoma (Disease) is palliated by Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Mannitol (Compound) causes Oropharyngeal pain (Side Effect) and Oropharyngeal pain (Side Effect) is caused by Nadolol (Compound) and Nadolol may lead to a major life threatening interaction when taken with Olodaterol
Mannitol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Carvedilol (Compound) and Carvedilol may lead to a major life threatening interaction when taken with Olodaterol